< Back to previous page
Researcher
Benoit Beuselinck
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Oncology (Division)
Member
From1 Feb 2011 → Today
Projects
1 - 10 of 12
- Understanding novel CD8+ T cell stress responses creating immunotherapy resistance in kidney cancer.From26 Nov 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Psychological suffering in cancer patients: impact of meaning in life on end-of-life decisionsFrom1 Oct 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- OPTIMIZATION IN THE MANAGEMENT OF METASTATIC RENAL CELL CARCINOMA WITH IMMUNE CHECKPOINT AND ANGIOGENESIS INHIBITORSFrom30 Jul 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Stratifying renal carcinoma patients using data-driven immune & epithelial landscapesFrom3 Feb 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Translational biomarker research in metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or angiogenesis inhibitorsFrom1 Jan 2025 → TodayFunding: Foundations, funds and other with scientific goal
- Deciphering the molecular determinants of circadian immune rhythms that govern immunotherapy responses in human and murine kidney cancerFrom3 Sep 2024 → TodayFunding: FWO fellowships
- Medication-related osteonecrosis of the jaw (MRONJ) - Balancing treatments benefits and risksFrom1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Response prediction in metastatic clear-cell renal cell carcinoma treated with angiogenesis and/or immune checkpoint inhibitorsFrom1 Oct 2020 → 11 Oct 2024Funding: Foundations, funds and other with scientific goal
- RESPONSE PREDICTION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TARGETED THERAPY AND/OR IMMUNE CHECKPOINT INHIBITORSFrom5 Dec 2019 → 30 Sep 2021Funding: BOF - projects
- RESPONSE PREDICTION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTORTARGETED THERAPY AND/OR IMMUNE CHECKPOINT INHIBITORSFrom1 Oct 2019 → 30 Sep 2024Funding: FWO fellowships
Publications
1 - 10 of 151
- Understanding the genetic basis of medication-related osteonecrosis of the jaw: A systematic review(2025)Published in: BONEISSN: 8756-3282Volume: 201
- CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).(2025)Published in: Clinical Genitourinary CancerISSN: 1558-7673Issue: 6Volume: 23Pages: 102431
- Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?(2025)Published in: Acta OncologicaISSN: 0284-186XVolume: 64Pages: 979 - 988
- Anti-TIF1-beta autoantibody-positive dermatomyositis: a case-based review(2025)Published in: Rheumatology InternationalISSN: 0172-8172Issue: 5Volume: 45
- Stereotactic Body Radiotherapy for Extracranial Oligometastatic Renal Cell Carcinoma: State of the Art and Future Perspectives(2025)Published in: Technology in Cancer Research and TreatmentISSN: 1533-0346Volume: 24
- Trial watch: anticancer vaccination with dendritic cells(2024)Published in: OncoImmunologyISSN: 2162-402XIssue: 1Volume: 13
- Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium(2024)Published in: EUROPEAN UROLOGYISSN: 0302-2838Issue: 6Volume: 86Pages: 488 - 492
- Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma(2024)Published in: ANNALS OF ONCOLOGYISSN: 0923-7534Issue: 12Volume: 35Pages: 1148 - 1156
- Response prediction in metastatic clear-cell renal cell carcinoma treated with angiogenesis and/or immune checkpoint inhibitors(2024)
- Cabozantinib Induces Isolated Hyperbilirubinemia in Renal Cell Carcinoma Patients carrying the UGT1A1*28 Polymorphism(2024)Published in: Clinical Genitourinary CancerISSN: 1558-7673Issue: 5Volume: 22